RxDoctor Payments Data

Ashley Hunter, MD

Family Medicine · Huntersville, NCNPI 1659877371

Payments from drug & device makers

$573in general payments, 2019–2025

Across 16 payments — averaging $35.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$291
  • Lilly USA, LLC$100
  • AbbVie$53
  • Zimmer Biomet$48
  • Pfizer$29
  • Abbott$23
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$291
Lilly USA, LLC1$100
AbbVie3$53
Zimmer Biomet1$48
Pfizer1$29
Abbott1$23
Amgen1$16
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$573 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$144,886
Medicare patients
377
Services billed
1,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide174$191,683
MounjaroTirzepatide134$147,268
EliquisApixaban92$84,948
JardianceEmpagliflozin45$64,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$32,286
XareltoRivaroxaban23$29,449
JanuviaSitagliptin Phosphate17$28,138
TrulicityDulaglutide15$25,556
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$17,183
RybelsusSemaglutide12$16,538
FarxigaDapagliflozin Propanediol24$14,646
Tresiba Flextouch U-100Insulin Degludec18$14,075
Advair HfaFluticasone Propion/Salmeterol11$7,235
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,137
Rosuvastatin Calcium451$5,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$291$208,222186 claims
Lilly USA, LLCMounjaro, Trulicity$100$172,824149 claims
PfizerEliquis$29$84,94892 claims
AstraZenecaFarxiga, Symbicort$14$19,55045 claims
AbbVieSynthroid$53$1,56529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →